Patents Examined by Audrea B Coniglio
  • Patent number: 10279010
    Abstract: The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: May 7, 2019
    Assignee: The Regents of the University of California
    Inventors: B. Chia Soo, Kang Ting, Zhong Zheng
  • Patent number: 10279077
    Abstract: A collagen-coated tissue based membrane that is smooth on both sides so as to inhibit cell and tissue adhesion. Also disclosed are methods for making a collagen-coated tissue-based membrane.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: May 7, 2019
    Assignee: Collagen Matrix, Inc.
    Inventors: Shu-Tung Li, Debbie Yuen
  • Patent number: 10278917
    Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 7, 2019
    Assignee: PERRIGO ISRAEL PHARMACEUTICALS LTD.
    Inventors: Marina Shevachman, Amira Ze' Evi, Eilon Asculai, Batella Binyaminovich, Nir Avram, Chaim Aschkenasy
  • Patent number: 10272092
    Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: April 30, 2019
    Assignee: The Catholic University of Korea Industry-Academic Cooperation
    Inventors: Seok Goo Cho, Keon-Il Im, Jung Yeon Lim, Nayoun Kim, Young Sun Nam, Eun Sol Lee
  • Patent number: 10233013
    Abstract: Agriculturally active products are disclosed that are used to eliminate or otherwise control pests.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 19, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Donald B. Campbell, James M. Breuninger, Charles W. Arnett
  • Patent number: 10213453
    Abstract: Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the first layer is a second layer comprising a mixture of a flavonoid and polysaccharide or polypeptide binder or polymer gel. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: February 26, 2019
    Inventors: Steven Loyd, George Blouin, Newsha Farahani, Robert Burns
  • Patent number: 10206881
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 19, 2019
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10211534
    Abstract: A pharmaceutical composition comprising a liquid carrier comprising water and at least 35% of ethanol and sildenafil citrate dissolved in said liquid carrier at a concentration of at least 7 mg/ml.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 19, 2019
    Assignee: Vigorous Solutions Ltd.
    Inventors: Morris Aboohi, Moshe Rogosnitzky
  • Patent number: 10188772
    Abstract: A medical device that releases a pharmaceutical agent to a target site is disclosed. The medical device includes a balloon, and a coating on at least a portion of the balloon. The coating includes particles of a pharmaceutical agent. Each particle of the particles of the pharmaceutical agent is at least partially encapsulated in a polymer material. A method of releasing a pharmaceutical agent at a target site is also disclosed. The method includes the steps of providing a device including a balloon, and a coating on at least a portion of the balloon, the coating including particles of a pharmaceutical agent, and each particle of the pharmaceutical agent is at least partially encapsulated in a polymer material; positioning the device to allow the balloon to reach the target site; and inflating the balloon of the device.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 29, 2019
    Assignee: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Meagan M. Fagan
  • Patent number: 10188598
    Abstract: The present disclosure provides a sterilized chlorhexidine product that comprises a package and a sterilized chlorhexidine article. The package defines an interior volume. The sterilized chlorhexidine article comprises a sterilized applicator and a sterilized antiseptic composition. The sterilized antiseptic composition comprises a sterilized solvent and a sterilized antibacterial agent dissolved in the solvent. The sterilized chlorhexidine article is disposed in the internal volume of the package. The sterilized chlorhexidine article has a Sterility Assurance Level of from 10?3 to 10?9. The present disclosure also provides a method for sterilizing the chlorhexidine article.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: January 29, 2019
    Assignee: Sage Products, LLC
    Inventors: Jennifer M. Allen, Christopher J. Grannis, Syed M. Hasan, Timothy P. Manthei, Niles R. Manwill
  • Patent number: 10172361
    Abstract: Nanoparticle composites comprised of a metal oxide and ions of a metallic element included within a crystal lattice of said metal oxide are disclosed. Process of preparing the nanoparticle composites per se and incorporated in or on a substrate are also disclosed. Uses of the nanoparticle composites and of substrates incorporating same, particularly for reducing a formation of a load of a microorganism or of a biofilm, are also disclosed.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: January 8, 2019
    Assignee: BAR-ILAN UNIVERSITY
    Inventors: Aharon Gedanken, Ehud Banin, Ilana Perelshtein, Rachel Lubart, Anat Lipovsky, Eyal Malka, Nitzan Yeshayahu, Nina Perkas, Yakov Shalom, Jonathan Lellouche, Tal Patick, Michal Eshed, Livnat Naparstek
  • Patent number: 10172913
    Abstract: An orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg is disclosed. The dosage unit consists of: (a) 5-100 wt. % of coated particles comprising 50-99 wt. % of a core particle and 1-50 wt. % of a coating that envelops the core particle, said coating consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-50 wt. % of buffering agent; 15-80 wt. % of branched glucan; 0-78 wt. % of other pharmaceutically acceptable ingredients; and (b) 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 20 ?g of the partus control substance and having a pH buffer range of 3.5-5.7.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: January 8, 2019
    Assignee: Oxytone Bioscience B.V.
    Inventors: Johannes Jan Platteeuw, Herman Jan Tijmen Coelingh Bennink
  • Patent number: 10159661
    Abstract: The present invention is directed to an injection syringe comprising an injectable composition, the composition comprising a penicillin, salt or prodrug thereof, one or more pharmaceutically acceptable excipients, and water, wherein the composition is free of a preservative agent. In other aspects, the invention relates to a process for producing the injection syringe, and a kit comprising the injection syringe.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: December 25, 2018
    Assignee: Sandoz AG
    Inventors: Christoph Bitter, Heiko Degendorfer, Johannes Raneburger
  • Patent number: 10149813
    Abstract: A hair care composition is provided imparting enhanced shine to hair comprising a) from about 0.1% to about 10.0% by weight of the composition of a non-volatile polysiloxane fluid; b) from about 0.02% to about 5.0% by weight of the composition of a surfactant mixture comprising a shining surfactant and a secondary surfactant, wherein the shining surfactant is a polyether siloxane copolymer; c) from about 0.003% to about 0.6% by weight of the composition of a rheology modifier comprising an acrylic acid/Vinyl ester copolymer; and d) a carrier suitable for the application to hair wherein the composition is free of ethanol and the viscosity s less than 7 Pa*s. Further a method is provided comprising spraying the composition with a particle size in the range of from about 0.01 ?m to about 10 ?m, wherein the resulting film is in the range of from about 100 nm to about 500 nm after drying.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 11, 2018
    Inventors: Michael Lee Vatter, Kelly Rose Kroger Lyons, Timothy Woodrow Coffindaffer, Mikah Coffindaffer, Simran Preet Kaur, Timothy James Felts, Scott Edward Smith, Samuel Wolfe Stofel
  • Patent number: 10143636
    Abstract: A porous silica particle optimized as the scrubbing agent is used for a cleansing cosmetic. The porous silica particle has an average circularity of 0.1 to 0.5, a pore volume of 1.0 to 2.0 ml/g, a mode diameter of 50 to 600 ?m, and a ratio of the maximum particle diameter to the mode diameter of 3.0 or less. The porous silica particle moreover has a median size of 0.5 to 25 ?m and the maximum particle diameter of 1 to 100 ?m, after rubbing with a load of 1.0 to 1.4 KPa for 30 seconds. With the cleansing cosmetic containing this particle, the skin is rubbed by the frictional force generated by the friction with the skin at the rubbing. Therefore, the mild peeling effect for the stratum corneum is obtained and the damage of the skin and the micro damage on the stratum corneum can be prevented.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 4, 2018
    Assignee: JGC Catalysts and Chemicals Ltd.
    Inventors: Satoshi Watanabe, Naoyuki Enomoto, Yasutaka Miyoshi, Michio Komatsu
  • Patent number: 10137222
    Abstract: A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 27, 2018
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Jason W. Bjork, Alexi J Young, Raha A. Been, Jana Ninkovic, Bryan A. Baker
  • Patent number: 10137068
    Abstract: A method for the color retention of dyed keratin fibers is provided herein. The method includes i. applying a cosmetic composition to dyed keratin fibers as a pretreatment agent for keratin. The method further includes ii. subjecting the keratin fibers to a dyeing and/or brightening within a period of about 5 seconds to about 24 hours after to step i. The cosmetic composition has, based on its own weight, from about 0.01 to about 4.00% by weight of at least one alum and a pH value in the range of about 2.5 to about 5.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: November 27, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Erik Schulze zur Wiesche, René Krohn
  • Patent number: 10130586
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: November 20, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10123950
    Abstract: Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: November 13, 2018
    Assignee: Laboratory Skin Care, Inc.
    Inventors: Zahra Mansouri, Rodica-Tatiana Canelide, Douglas Thomas, Tetsuro Ogawa
  • Patent number: 10117429
    Abstract: A granular pesticidal composition in which a powdery pesticide is aggregated and coated with a thermosetting resin is capable of enabling a pesticidal active ingredient to be controlled-released. Further, the controlled-release pesticidal granule can be produced by mixing a powdery pesticide with a first liquid component serving as a raw material for a thermosetting resin, a process of adding a second liquid component serving as a raw material for a thermosetting resin, and then making the first liquid component react with the second liquid component to produce a thermosetting resin.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 6, 2018
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Manabu Tagami, Nobuhito Ueda